Last reviewed · How we verify
A Phase I/II Study of GW572016 in Patients With Recurrent Malignant Glioma
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of lapatinib and to see how well it works in treating patients with recurrent glioblastoma multiforme.
Details
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | COMPLETED |
| Enrolment | 24 |
| Start date | 2004-12 |
| Completion | 2007-11 |
Conditions
- Brain and Central Nervous System Tumors
Interventions
- lapatinib ditosylate
Primary outcomes
- Toxicity for phase I assessed by CTCAE v.3.0 MacDonald criteria — 7 years
- Response for phase II — 7 years
Countries
Canada